| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882967 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 6 Pages |
Abstract
At present, management strategies are aimed at treating the MPN and regularly monitoring the MGUS for transformation to an overt plasma-cell malignancy. However, for patients who develop overt MM, management is focused more on treating the myeloma and monitoring the MPN. It has not yet been definitively shown that these 2 entities arise from a common-ancestor hematopoietic stem cell.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jyoti Malhotra, Marina Kremyanskaya, Emily Schorr, Ronald Hoffman, John Mascarenhas,